Latest News and Press Releases

ATLANTA, June 03, 2025 (GLOBE NEWSWIRE) --  Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (“Dogwood” or the “Company”), a development-stage biotechnology company developing new medicines to treat pain...

SPRINT® PNS meets the primary endpoint of reduction in head pain in the first publication of multicenter prospective MONARCH™ Study.

- Dogwood Therapeutics, Inc. commenced dosing of patients in the Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2b Study - - Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2b study...

BELLEVUE, Wash., May 08, 2025 (GLOBE NEWSWIRE) -- Today, Truveta announced a new era in cancer research with more than 7 million oncology patient journeys spanning more than 100 cancer types,...

SPR announces publication of four-year follow-up data demonstrating significant and sustained low back pain relief following SPRINT PNS treatment.

ATLANTA, April 03, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a development-stage biopharmaceutical company focused on developing new medicines to treat pain...

-Dogwood Therapeutics, Inc. commenced dosing of patients in the Halneuron® Chemotherapy Induced Neuropathic Pain (“CINP”) Phase 2b Trial - - Halneuron® CINP P2b study interim data readout is expected...

ATLANTA, March 18, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (“Dogwood” or the “Company”), a development-stage biopharmaceutical company focused on advancing first-in-class,...

Indianapolis, March 10, 2025 (GLOBE NEWSWIRE) -- Longevity Life Advisors announces the launch of CancerEDGE, a first-of-its-kind program designed to provide genomic testing and precision health...

SUNNYVALE, Calif., Jan. 27, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [NASDAQ: BCDA] today announced that the results of its double-blind randomized placebo-controlled CardiAMP HF Phase 3 study have...